223 related articles for article (PubMed ID: 19523174)
21. Survival of patients with idiopathic pulmonary arterial hypertension after listing for transplantation: impact of iloprost and bosentan treatment.
Dandel M; Lehmkuhl HB; Mulahasanovic S; Weng Y; Kemper D; Grauhan O; Knosalla C; Hetzer R
J Heart Lung Transplant; 2007 Sep; 26(9):898-906. PubMed ID: 17845928
[TBL] [Abstract][Full Text] [Related]
22. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.
Sitbon O; Gressin V; Speich R; Macdonald PS; Opravil M; Cooper DA; Fourme T; Humbert M; Delfraissy JF; Simonneau G
Am J Respir Crit Care Med; 2004 Dec; 170(11):1212-7. PubMed ID: 15317666
[TBL] [Abstract][Full Text] [Related]
23. Sarcoidosis-associated pulmonary hypertension: a role for endothelin receptor antagonists?
Pitsiou GG; Spyratos D; Kioumis I; Boutou AK; Nakou C; Stanopoulos I
Ther Adv Respir Dis; 2009 Jun; 3(3):99-101. PubMed ID: 19638368
[TBL] [Abstract][Full Text] [Related]
24. Dual endothelin receptor antagonism in pulmonary arterial hypertension.
Pittrow D; Kirch W
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():v-vi. PubMed ID: 16919003
[No Abstract] [Full Text] [Related]
25. Bosentan for idiopathic pulmonary fibrosis.
King TE
Curr Opin Investig Drugs; 2008 Nov; 9(11):1171-9. PubMed ID: 18951296
[TBL] [Abstract][Full Text] [Related]
26. [Bosentan for treatment of heart failure].
Yoshimoto T; Hirata Y
Nihon Rinsho; 2007 May; 65 Suppl 5():159-63. PubMed ID: 17571378
[No Abstract] [Full Text] [Related]
27. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.
Hiramoto Y; Shioyama W; Higuchi K; Arita Y; Kuroda T; Sakata Y; Nakaoka Y; Fujio Y; Yamauchi-Takihara K
J Cardiol; 2009 Jun; 53(3):374-80. PubMed ID: 19477379
[TBL] [Abstract][Full Text] [Related]
28. Combined endothelin receptor antagonist and transcatheter interventional therapy of patent ductus arteriosus with severe pulmonary artery hypertension.
Ussia GP; Mulè M; Caruso E; Aiello R; Tamburino C
Int J Cardiol; 2007 Apr; 116(3):427-9. PubMed ID: 16875749
[TBL] [Abstract][Full Text] [Related]
29. Response to bosentan in children with pulmonary hypertension.
Maiya S; Hislop AA; Flynn Y; Haworth SG
Heart; 2006 May; 92(5):664-70. PubMed ID: 16216850
[TBL] [Abstract][Full Text] [Related]
30. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
31. [Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study].
Castro G
Rev Port Cardiol; 2001 Nov; 20(11):1151-2. PubMed ID: 11826707
[No Abstract] [Full Text] [Related]
32. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension.
Dhillon S; Keating GM
Am J Cardiovasc Drugs; 2009; 9(5):331-50. PubMed ID: 19791841
[TBL] [Abstract][Full Text] [Related]
33. [Young patient with stress dyspnea of uncertain origin. Evaluate for pulmonary hypertension!].
MMW Fortschr Med; 2002 Oct; 144(42):64. PubMed ID: 12534004
[No Abstract] [Full Text] [Related]
34. Bosentan therapy for portopulmonary hypertension.
Hoeper MM; Halank M; Marx C; Hoeffken G; Seyfarth HJ; Schauer J; Niedermeyer J; Winkler J
Eur Respir J; 2005 Mar; 25(3):502-8. PubMed ID: 15738295
[TBL] [Abstract][Full Text] [Related]
35. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators.
Krum H; Viskoper RJ; Lacourciere Y; Budde M; Charlon V
N Engl J Med; 1998 Mar; 338(12):784-90. PubMed ID: 9504938
[TBL] [Abstract][Full Text] [Related]
36. Endothelin receptor antagonist bosentan improves the dermal sclerosis in a patient with systemic sclerosis.
Nishibu A; Sakai E; Oyama N; Yamamoto T
Australas J Dermatol; 2012 May; 53(2):e32-3. PubMed ID: 22571581
[TBL] [Abstract][Full Text] [Related]
37. Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension.
Hamaguchi Y; Fujimoto M; Hasegawa M; Matsushita T; Takehara K
J Dermatol Sci; 2009 Jul; 55(1):66-7. PubMed ID: 19342201
[No Abstract] [Full Text] [Related]
38. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
39. Clinical features and endothelin receptor antagonist in primary Sjögren's syndrome with pulmonary arterial hypertension.
Chen CH; Chen HA; Yang KY; Yu WC; Liao HT; Huang DF
Scand J Rheumatol; 2006; 35(3):245-7. PubMed ID: 16766376
[No Abstract] [Full Text] [Related]
40. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C.
Grander W; Eller P; Fuschelberger R; Tilg H
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():67-70. PubMed ID: 16919014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
